Kensington Investment Counsel’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Kensington Investment Counsel’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-58,599	Closed	-$342K	–	84
2022 Q4	$342K	Sell	58,599 -18,202	-24%	-$95.7K	0.27%	76
2022 Q3	$515K	Buy	76,801 +447	+0.6%	+$2.71K	0.43%	71
2022 Q2	$321K	Sell	76,354 -395	-0.5%	-$1.56K	0.27%	76
2022 Q1	$259K	Sell	76,749 -8,734	-10%	-$27.7K	0.17%	86
2021 Q4	$269K	Buy	+85,483	New	+$284K	0.16%	86
2021 Q2	$356K	Buy	84,368 +1,966	+2%	+$8.32K	0.24%	82
2021 Q1	$411K	Buy	82,402 +6,869	+9%	+$55.5K	0.31%	79
2020 Q4	$955K	Buy	+75,533	New	+$861K	0.79%	65

Kensington Investment Counsel's CNCE Position: Q1 2023 in Review

Kensington Investment Counsel sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 58,599 shares — an estimated $342K sold.

Kensington Investment Counsel first reported a position in CNCE in Q4 2020 and held it in 8 quarters. The position peaked at $955K in Q4 2020. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.

Kensington Investment Counsel reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
Kensington Investment Counsel sold 58,599 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $342K.
Kensington Investment Counsel first reported a position in Concert Pharmaceuticals, Inc. in Q4 2020 and held it in 8 quarters.
Kensington Investment Counsel's Concert Pharmaceuticals, Inc. position peaked at $955K in Q4 2020.
0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.

Based on Kensington Investment Counsel's 13F filing for Q1 2023, filed 11 May 2023.